Tackling type 1 diabetes: new immune-modulating drugs attack the root cause.
Shekhar
Chandra
C
chandra@nasw.org
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use; D017252:CD3 Complex / Q000276:immunology; D002986:Clinical Trials as Topic; D003922:Diabetes Mellitus, Type 1 / Q000276:immunology / Q000628:therapy*; D005968:Glutamate Decarboxylase / Q000276:immunology; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000627:therapeutic use*; D007165:Immunosuppression Therapy / Q000379:methods*; D016233:Immunotherapy, Active / Q000379:methods; D050417:Insulin-Secreting Cells / Q000276:immunology / Q000378:metabolism
D000911:Antibodies, Monoclonal; D017252:CD3 Complex; D007155:Immunologic Factors; D005968:Glutamate Decarboxylase